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S_..ary The pharmaceutical formulation of a new anti-tumour agent has often been perceived as the
bottleneck in anti-cancer drug development. In order to increase the speed of this essential development step,
the Cancer Research Campaign (CRC), the European Organization for Research and Treatment of Cancer
(EORTC) and the National Cancer Institute (NCI) agreed in 1987 to form the Joint Formulation Working
Party (JFWP). The main goal of the JFWP is to facilitate the rapid progress of a new drug through
pharmaceutical developmental to preclinical toxicology and subsequently to phase I clinical trial. Under the
auspices of the JFWP around 50 new agents have been developed or are currently in development. In this
report we present our formulation experienc since the establishment of the JFWP with a seklcted number of
agents: aphidicolin glycinate, bryostatin 1, carmethizole, carzelesin, combretastatin A4, dabis maleate, di-
sulphonated aluminium phthalocyanine, E.O.9, 4-hydroxyanisole, pancratistatin, rhizoxin, Springer pro-drug,
SRI 62-834, temozolomide, trimelamol and V489. The approaches used and problems presented may be of
general interest to scientists in related fields and those considering submitting agents for development.
Keyword& formulation; investigation of cytotoxic drugs; clinical trials; Joint Formulation Working Party
Anti-tumour agents represent a unique pharmacological
group since they are chemically variable and initial human
phase I clinical trials are conducted not in volunteers but in
patients. Additionally, it is important to determine rapidly if
any new agent arising from current research may represent
an advance on contemporary therapy. The bridge between in
vitro agent and useful medicine is crossed by the application
of pharmaceutical techniques to produce a product that
embodies the principles of safety, quality and efficacy. How-
ever, the pharmaceutical formulation of a new antineoplastic
agent involves a variety of stages and has often been
perceived as a bottleneck in drug development because of the
time required.
The formulation process necessitates a thorough
identification and characterisation of the raw material, in-
cluding determination of physicochemical properties such as
stability and solubility. A formulation (normally parenteral)
is then developed, its suitability assessed and appropriate
manufacturing methods determined (see Vezin and Salole,
1993, for a full exposition of this process). The formulated
products are then subjected to preclinical toxicology studies
and subsequently clinical trials; throughout this process a
number of hurdles may arise which can delay or block
development.
In 1987 the Cancer Research Campaign (CRC), the
European Organization for Research and Treatment of
Cancer (EORTC) and the National Cancer Institute (NCI)
agreed to form the Joint Formulation Working Party
(JFWP) in which formulation scientists collaborate in the
pharmaceutical development of investigational anti-cancer
drugs. The JFWP ensures international continuity and
through application of quality control, good laboratory prac-
tice (GLP) and good manufacturing practice (GMP), high
quality standards during pharmaceutical development. In
1988 the JFWP pubhshed formulation guidelines for inves-
tigational cytotoxic drugs (Davignon et al., 1988) which have
contributed to a more standardised approach to phar-
maceutical development in Europe and the United States.
This standardisation of formulation design should aid in the
transfer of technology, allowing simultaneous drug develop-
ment in several countries.
In this paper we describe a selection of investigational
agents that were developed under JFWP auspices and which
are now at different developmental stages. The cases present-
ed significant formulation challenges, and to categorise these
examples they have been grouped under four headings:
analytical, solubility, stability and excipient problems. It
should be noted, however, that several compounds presented
challenges in all areas! Many of the problems have been
resolved with unique approaches which may be beneficial in
related scientific fields; unfortunately, in some cases, an ans-
wer has yet to be found and development is currently
stymied.
All research processes require a suitable specific and
interference-free analytical technique to measure the com-
pound under test. To ensure assay integrity therefore requires
consumption of material through induced breakdown to pro-
duce possible interfering degradation products. Since the
majority of these experimental compounds are in short sup-
ply, assay development can be restricted but is still necessary
to produce a validated assay. The majority of drugs contain
chromophores, therefore simple spectrophotometric techni-
ques may be applied; occasionally unusual approaches may
have to be adopted because of the compound's chemical
properties.
Bryostatin I
Bryostatin 1 (NSC-33955, Figure 1) is a macrocyclic lactone
only available from its natural source, the marine bryozoan
Bugula neritina (Linnaeus) (Pettit et al., 1982). Since the
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Figwe 1 Chemical structure of bryostatin 1.
outset bryostatin 1 was in extremely short supply, with only
20 mg available, stability and preformulation work was con-
ducted using a small proportion of this sample. Additional
probkms were presented by the compound's high potency
and attendant toxicological implications; the estimated star-
ting dose was around 5 1zg m-2. However, the techniques
adopted to ensure minimal drug losses during transference
also minimised the risk of accidental exposure.
The lack of available material precluded a complete
solubility investigation in a range of pharmaceutically accep-
table solvents. Formulation was based on data from the
drug's discoverers, which demonstrated bryostatin's lmited
aqueous solubility (Pettit et al., 1982); ethanol was therefore
chosen as a prospective solvent. The solubility of ethanolic
solutions was investigated using modified protocols to keep
the volumes used as low as possible. At predicted formula-
tion concentrations the drug precipitated when the percen-
tage of ethanol fell below 50%. These experiments were
conducted on the assumption that the eventual formulation
should be capable of in-line filtration through a 0.22 iM filter
during administration. In the phase I dinical trial the ethanol
solution was diluted well below 50% in an attempt to reduce
phlebitis, thought to be associated with the high ethanol
concentration. No in-lne filter was used and there were no
reported problems with emboli caused by precipitated drug.
The use of administration sets with such low drug doses
and concentrations necessitated that compatibility and
adsorption studies be conducted using appropriate plastics. It
was found that if polytetrafluorethylene (PITFE)-lined plastic
was not used (e.g. polyvinylchloride, PVC) there was exten-
sive adsorption onto administration set surfaces. The adsorp-
tion was also significant with FIFE-lined sets when the
ethanol concentration fell below 50%. The phlebitis was
clinically addressed using in-line dilution with saline. There
was initial concern when it was suggested that the total dose
may not be delivered owing to precipitation or adsorption.
However, later in the trial the major toxicity was a general
myalgia present whether or not the drug was subject to
in-line dilution, suggesting that a significant amount of
bryostatin was being delivered.
During preclinical toxicology studies, there were major
investments in the isolation and purification of > 10 g quan-
tities of bryostatin 1, which permitted the development of a
more acceptable lyophilised formulation from a 50:50 t-
butanol-water solution containing polyvinylpyrrolidone
(bulking agent). The lyophilised product is reconstituted with
polyethylene glycol 400-ethanol-polysorbate 80 (60:3010,
v/v/v) and then further diluted with saline before administra-
tion (Flora et al., 1993). This product is currently being
evaluated in phase II cinical trials against renal cell car-
cinoma and non-Hodgkin's lymphoma. Work on this com-
pound demonstrates what can be achieved when very limited
supplies of material are available. However, it should be
recognised that severe compromises had to be accepted in the
volume of data that would usually be required in the for-
mulation development process.
Dabis maleate
Dabis maleate (NSC-262666, Figure 2) (Tagliabue et al.,
1992) is an example of a drug whose pharmaceutical develop-
ment was delayed owing to inadequate analytical method-
ology. The molecule is the dimaleate salt of 1,4-bis(2'-
chloroethyl)-l,4-diazabicyclo[2.2.1Jhptane. It contains two
quaternary nitrogens but lacks a chromophore that could be
used for ultraviolet (UV) detection following high-per-
formance liquid chromatographic (HPLC) separation. This
analytical problem was solved by the use of a 1i-Bondapak
phenyl column using a mobile phase containing naphthalene
sulphonic acid as an ion-pair reagent. The naphthalene sul-
phonic acid provided an indirect visuasation reagent since
the drug-ion pair had a reduced UV adsorption at 260 nm
and could be seen as a negative peak eluting from the
column. This method also had the advantage ofbeing able to
quantify the malekic acid. The developed methodology
enabled the preformulation and stability studies to be con-
ducted in the normal way. In phase I studies using an
administration schedule of once every 3 weeks the dose-
lmiting toxicity was neurotoxicity and the recommended
dose for phase II trials was 750mgm-2 (van der Burg et al.,
1991). Prolonged infusion resulted in neurotoxicity consisting
ofparasthesia and ataxia, with a recommended phase H dose
of 500 mg m2 week-' as a 6 h infusion for 6 weeks followed
by a 3 week drug vacation (Verweij et al., 1992). Currently,
phase II studies are planed within the framework of the
EORTC Early Clinical Trials Group and the EORTC New
Drug Development Office.
Disuiphonatedalwniniw phthalocyanine
The (di-)sulphonated aluminium phthalocyanines (Figure 3)
are photodynamic compounds designed to be activated via
extemal laser irradiation. They are complex macrocyclic
mokcules with degrees of sulphonation varying from 1 to 4,
and the position of the sulphate groups within the molecule
can also differ. The biological properties of the isomers
within one group are similar, so there is no real justification
for undertaking very expensive procedures to prepare a single
Cl-CH2CH2-+N-CH2-N-CH2CH2-Ci
CHCOO-
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Fgwe 2 Chemical structure of dabis maleate.
Figwe 3 Chemical stnruu of disulphonated aluminium
phthalocyamne.
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purified isomer. The major issue was one of purifiction,
characterisation and development of an analytical
methodology for quality control and preformulation studies.
The final purification step uses HPLC, and a imilar
reversed-phase gradient method was adapted for quality con-
trol of the bulk material. This method has been used to place
limits on the major components in the drug and for stability
stud[ies on the bulk chemical. Work is currently in progress
to use the same semipreparative HPLC technology to prepare
small amounts of pure reference matenal which can then be
thoroughly characterised by nuclear magnetc resonance
(NMR) and mass spectrometry (MS). The compound is still
under active development.
Sd
The most common route of adminiStration of anti-cancer
compounds for phase I chnical trial is intravenous injection,
which requires formulation of an aqueous or biocompatible
solution. One of the major problems associated with this is
achieving a suitable level of drug solubility, especialy sine
the majority of agents are hydrophobic in nature. If this is
not possible, biocompatible non-aqueous solvents or other
approaches such as surfactants or emulsions can be used. In
some cases several techniques may have to be married
together to obtain a suitable formulation.
Aphidicolin glycinate
Aphidicolin (NSC-234714) is a tetracyclic diterpene isolated
from Cephalosporiwn aphidicola (Brundret et al., 1972) which
is reported to inhibit DNA polymerase z and to have
antimitotic, antiviral and anti-tumour activity (Bucknall et
al., 1973; Taguchi et al., 1978). The last-mentioned property
was observed at the National Cancer Institute in B16
melanoma and colon 26 tumour. Aphidicolin is extrmely
insoluble in water (-0.25 mg ml-') and does not contain
ionisable groups, which may be exploited to enhance
solubility through salt formation. Co-solvents or surfactants
did not increase solubility to cinically useful kleels; eventual
clinical doses in phase I trials sponsored by the EORTC on
the glycinate ester were up to 2250 mgm-' as a I h infusion
and up to 4500 mg m-2 as a 24h infusion. ICI Phar-
maceuticals esterified the hydroxyl group at the 17 position
on aphidicolin to produce aphidicolin glycinate (NSC-
303812, ICI 137233, Figure 4), which was active against B16
melanoma and P388 leukaemia. A hydrochloride salt of the
glycine amino group could be easily prepared with a
solubility greater than 100mgnml'.
Stability studies of aphidicolin glycinate vs pH (pH values
of 2.0, 4.0, 4.5, 6.5, 7.0 and 9.0) at 40-C showed that max-
imnal stability was at pH 4.5 with significntly ireasd
decomposition at pH values of 6.5 and above. This study
also indicated that a liquid-filled product was not a feasible
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option because oflow long-term stability. A dosage form was
developed consisting of 250 mg of aphidicolin glycinate and
50 mg of mannitol freeze dried from water for injection. The
vial contents were reconstituted with 2.4ml of water for
injection, to yield a l00mgml-' solution which was stable
for at least 24h. Further dilution to 1 mg ml-' in 5% dext-
rose or 0.9% sodium chloride injection provided solutions
stable for more than 24 h as determined by HPLC analysis.
However, the use time for this unpreserved product is limited
to 24h owing to sterility considerations. The toxicity and
pharmacokinetics of aphidicolin glycinate were evaluated in
two phase I studies, using a 1 h infusion for five consecutive
days every 3 weeks and a 24 h infusion every 3 weeks. Local
toxicity was dose limiting in both studies at 2250mgm-2 and
4500 mg m-2 (Sessa et al., 1991); however, since phar-
macologically active levels had not been achieved, it was
decided to cease evaluation.
Carmethizole hydrochloride
Anderson and Corey (1977) synthesised a series of subs-
tituted pyrrolizine derivatives as potential anti-tumour
agents. One of these compounds (NSC-278214) was chosen
by the NCI for further development based on its activity in
several solid tumour models. Unfortunately, this compound
has negligible solubility in water and is extremely chemially
unstable, for example the half-life in 66% aqueous acetone at
25 C is only about 5 mi. A formulation was developed
(El-Sayed and Repta 1983) which required extemporaneous
incorporation into a 10% fat emulsion (Intralipid) by addi-
tion of the drug as a concentrated solution in N, N-
dimethylacetamide (DMA)/Cremophor EL. The emulsion
poduct contained NSC-278214 at 0.7 mgml-' and also 1%
DMA and 5% Cremophor EL; in this system about 10% of
drug decomposed in 2 h. Owing to the substantial amounts
of DMA and the drug's rapid decomposition, efforts were
begun to prepare analogues of NSC-278214 with more
favourable solubility and stability characterstics. Accord-
ingly, Anderson and Corey (1977) prepared soluble
analogues of NSC-278214 from which carmethizole hydroch-
loride (NSC-602668, Figure 5) was chosen as a lead can-
didate for further development. Carmethizole hydrochloride
was active aginst human tumour xenografts in athymic
mice, incluxing the LOX amelanotic melanoma, MX-1 mam-
mary carcinoma and NCI-H82 small-cell hmg carcinoma
(Waud et al., 1992). Formulation-rdated studies on the
stability and mhanism of decomposition of carmethizole
hydrochloride have been described (Stella et al., 1991).
Solubility of the hydrochloride salt is greater than
500mg ml-1, and the stability varies as a function ofsolution
pH, with maximal stability at about pH 1 or kw.
Freezedrying of drug (250mg) in the preWnce of mannitol
(250mg) produced a cake with acceptable appearance which
could be reconstituted with water for injection within
1-2 min The solution pH was 2.8 and the teA was approx-
imately 5.4 h. The pharmaceutical properties of amehizole
hydrochloride were significantly more manageae than those
of the original ead compound (NSC-278214). Unfortunately,
signifiant cardiotoxicity was observed during preclinical tox-
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icology studies and development of the compound was ter-
minated.
Carzelesin
Carzeesin (U-80,244, NSC-619029, Figure 6), a synthetic
cyclopropapyrroloindole derivative, is a very potent novel
anti-cancer drug with stnrctural similarities to the extremely
potent cytotoxic antibiotic CC-1065 (Kelly et al., 1987). This
type of agent has a high affinity for minor groove adenine/
thymine-rich base sequences within DNA without undergoing
intercalation. Adozelesin (U-73,975) is a closely related com-
pound of carzelesin and is under current development by
Upjohn (Li et al., 1991). Carzelesin was found to have very
low solubility in common pharmaceutically acceptable
solvents with an aqueous solubility measured in pg ml-'. As
a result of solubility and stability data, feasibility studies
were iuntiated to produce a co-solvent concentrate that could
be diluted before administration. Toxicologially, when using
co-solvents it is advisable to use those that are already
present in other commercially available formulations and of
which there exists experience in the clinic. The proposed
formulation for carzelesin resembles that of etoposide (VP-
16, Vepesid), which is formulated in a vehicle containing
polysorbate 80, polyethylene glycol 300 and ethanol with
minor quantities of citric acid and benzyl alcohol. Carzelesin
was formulated in a mixture of polyethylene glycol 400
(60%), polysorbate 80 (10%) and ethanol (to 100%) (PET).
Accelerated stability studies in this vehicle at 40C demon-
strated that the first degradation product arises rapidly
through hydrolysis of the ester function. However, when
stored at - 30C the drug is stable in PET for at least 1 year.
Separate drug and diluent ampoules (2 ml = 500 pg of drug
and 10 ml of PET respectively) were manufactured for the
phase I clinical trial. Before use at dosages <500 pg the
carzelesin concentrate is diluted to 1:10 stregth with PET
vehile (dosages >500 pg are not diluted). Next, the appro-
priate volume is further diluted to a final volume of 20ml
with 5% dextrose and infused at a specified rate into a
flowing i.v. ie containing 5% dextrose. Two phase I studies
of carzelesin are on-going, with administration either as a
10 min infusion daily for 5 days every 4 weeks or once every
4 weeks. No conclusive results are yet available.
the physicocheical properties of combretastatin A4 ensured
that these attempts ended in failure. It was then decided to
use a prodrug approach, and a number of esters and car-
bamates were made. The phosphate ester proved to have
adequate solubility and stability in aqueous solutions and
released the parent mokcule when incubated with acid or
alkaline phosphatase. Unfortunately, it was inactive in vim,
and current research is directed towards identifying other
suitable prodrugs.
E.O.9
E.O.9 (NSC-382456, Figure 8) is one of the lead compounds
belonging to the group of aziridinylquinones (Oostveen and
Speckamp 1987), which are bioreductive alkylating agents
believed to exert cytotoxicity after bioactivation (Walton et
al., 1992). The compound is synthesised through a complex
and lengthy (>20 steps) pathway and is chemically stable in
the solid state. After full analytical characterisation, includ-
ing spectroscopic (NMR, MS, UV, IR) and chromatographic
thin-layer chromatography (TLC), HPLCJ analysis and
measurement of other physal constants such as the melting
point, the batch with the highest purity was seleted as
reference standard and used for comparison of other batches.
From the animal toxicology study it was anticipated that
vials containing about 5-0mg of drug would be adequate
for the phase I study. In aqueous solution E.O.9 is degraded
by a process that is accekrated by extremes of pH and high
temperatures. At pH values below 7 E.O.9 degrades to
E.O.5A by hydrolysis of the aziridine function in the quinone
ring system to yield an ethanolamine group. In alkaline
solution (pH>10) the 7-aziridinyl moiety is replaced by a
hydroxyl function. At intermediate pH values (7-10) both
degradation products are detected, and the pH of maximum
stability is around 9.5 (de Vries et al., 1993). E.O.9 also has
lmited aqueous solubility and is poorly soluble and stable in
other pharmaceutically acceptable vehicles. A freeze-dried
formulation was therefore developed, based on dissoling
E0.9 in water for injection, adjusting to pH 9.5 with sodium
hydroxide for maximum stability and adding lactose as a
bulling agent. Sterilisation was performed by membrane
filtration, which has the additional advantage of removing
Combretastatin A4
Combretastatin A4 (NSC-81373, Figure 7) is a natural prod-
uct, isolated from the dry stem wood of the South African
tree Combretwn caffrwn (Pettit et al., 1989). It is a subs-
tituted stilbene with methoxy functional groups and one
phenolic hydroxyl group with excellent in vitro anti-tumour
activity but no significant in vivo activity. The formulation of
combretastatin A4 was problematical because of the drug's
limited aqueous solubility and chemical instability in solu-
tion, which was exacerbated by light. The most promising
formulation was one using the PET solvent system listed
above; however, in a preliminary murine toxicological study
it was evident that there was severe irritation at the injection
site. It was therefore necessary to investigate the use of
co-solvents in limited in vivo experiments. Attempts were also
made to use other formulation systems, e.g. emulsions, but
ci
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undisolved particles. Because of the low aqueous solubility
(0.2-0.5 mgml-') and high dose (5-10mg), it was nessy
to lyophilis E.O.9 from a relatively large volume. An 8 mg
vial required the lyophilisation of 40ml of water, which
prolongs the freezedrying cycle to 3 days. Shelf-life studies
have demonstrated that the lyophiised formulation is stable
for at least I year when stored at 4C. The freeze-dried E.O.9
rapidly and completely dissolves on reconstitution with 0.9%
sodium chloride, providing an isotonic solution (0.5 mg ml-1)
stable for at least 24h at room temperature. The drug is now
being evahuated in phase II clnical trials against breast,
gastric, colorectal, pancreatic and non-small-cell lung cancer.
Pancratistatin
Pancratistatin (NSC-349156, Figure 9) possesses anti-cancer
and antiviral activity (Gabrielsen et al., 1992) but is poorly
solube Iess than 0.4mgml-') in a range of solvents
[aqueous, alcoholic, aqueous dimethylsulphoxide (DMSO),
dimethylformamide (DMF) and DMA]. The aqueous
solubility is signifiantly enhanced by nicotinamide at
150mgml-', which acts as a complexing agent providing
pancratistatin solubilisation to 1 mgml-'. Lyophilisation in
the presence of nicotinamide resulted in cakes which were
readily reconstituted in water to provide solutions with a pH
value of 6.3. The lyophilised product (5 mg of drug and 600
or 800mg of nicotinamide per vial) was satisfactory in
appearance, however after storage at room temperature for 2
months reconstitution was problematical. Feasibility studie
for a liquid formulation were also conducted, but the solu-
tion became light yellow in colour and further darkening
occurred with ageing. The development of colour was
effectively inhibited by the addition of a chelating agent (1%
EDTA) and the use of nitrogen atmosphere. In contrast, the
antioxidant sodium bisulphite greatly enhanc colour
development during storage. Unfortunately, the anticipated
clinical doses of pancratistatin are relatively high, which
would require the administration of unacceptably high levels
of nicotinamide. Alternative formulations based on the mic-
rosuspension method of Violante (Sands et al., 1987) were
unsuccessful. Recently, the ability of hydroxypropyl-p-
cyclextrin (HPCD) to enhance the solubility of pancratis-
tatin was evaluated. A 40% aqueous solution of HPCD was
found to solubilise approximately 1.2 mgml-' of drug
(Torres-Labandeira et al., 1991). This level of solubility is,
however, not sufficient for clinical use, and at present
development is on hold awaiting the synthesis of prodrugs.
Rhizoxin
Rhizoxin (NSC-332598, Figure 10) is a 16-membered antifim-
gal macrocycic lactone isolated from the plant pathogenic
fungus Rlzizopus chnensis (Iwasaki et al., 1984). It has potent
antifungal as well as cytotoxic activity. Chemically it is uns-
table and is an example of a new cytotoxic drug with very
poor water solubility (12jigml-'). For initial studies it was
necessary to develop a parenteral dosage form of rhizoxin
containing 1 mgml-'. In order to obtain the desire stabilty
and concentration, a number of solubility and stability char-
acteristics were examined. Since rhizoxin has no ionisable
groups and has poor water solubility, the only route capable
of achieving the desired solubility, other than chemical
modification, is the use of complexation, micellar solubilisa-
tion or co-solvents. Complexation was ruled out because of
the 100-fold increase in solubility that would be required and
micellar solubilisation, since cremophors have been
associated with incidences of anaphylaxis. Success was
achieved by using a co-solvent system containing 40% pro-
pylene glycol-10% ethanol-water, and stability studies
revealed that the maximum stability occurred at pH
5.6 ± 0.1. Degradation products observed at acidic pH values
are probably the result of acid-catalysed cleavage of the
lactone ring(s) and/or both of the epoxide rings, while
alkaline treatment most probably produces a carboxylic acid,
resulting from cleavage of rhizoxin's larger lactone ring. The
first-order kietics of degradation in vanous alcoholic
solvents demonstrated that rhizoxin is signintly more
stable in alcohol than in purely aqueous systems. As
powdered rhizoxin is subject to photochemical degradation,
experiments were performed to examine its behaviour in the
presence and absence of light. In aqueous and alcoholic
solutions, especially at acidic and alkalie pH, the degrada-
tion kinetics did not appear to be particularly sensitive to
light. In contrast, at pH 5.6 in presence of light there was an
approximately 2-fold increase in degradation compared with
solutions protected from light. This data indicated that
rhizoxin was not suitable for formulation as a ready-made
aqueous or alcoholic solution and the very poor water
solubility prohibited freezedrying from aqueous solutions.
The solubility in t-butanol and t-butanol-watermixtures
was, however, excellent, and these solvents, which are also
used in other pharmaceutical preparations, could therefore be
used to prepare freeze-dried samples of rhizoxin (Stella et al.,
1988). Excellent freeze-dried cakes were prepared from a
40% t-butanol-water mixture using mannitol as a bulking
agent. The freeze-dried formulation containing 5 mg of
rhizoxin could be reconstituted with 5 ml of the sterile sol-
vent 40% propylene glycol-10/% ethanol-water to give a
rhizoxin concentration of 1 mgml-'. Interestingly, decom-
position product analysis from freeze-dried samples did not
produce the same pattern as noted during the hydrolytic
studies. Oxidative breakdown was suspected because of the
extended conjugated double-bond system, a theory supported
by the fact that ascorbic acid signiinty enhanced the solid
state stability. At present, phase H trials with this agent in
colorectaL ovarian, renaL breast melanoma and non-small-
cell lung cancer are almost complete.
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A particularly important property of any formulation is
chemical stability and a reasonable shelf-life, usually at kast
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3 to 6 months before firther testing can proceed. Thus
stability testing plays an important role in drug development
and is an area which due to its very nature adds time to the
overall process. Additionally these studies consume large
quantities of agent at a time when it may be in short supply.
The diverse ch l nature of anti-cancer drugs coupled
with their well known reactivity often leads to stability prob-
lems some of which only become evident on prolonged
storage. In the majority of cases removal of the solvent by
lyophilisation provides adequate stability, however critical
limits may have to be set on residual solvents. In some cases
even the lyophlised product may exhibit instability which
may be physical rather than chemical.
Springerprodrug
The Springer prodrug (Figure 11) presented a unique for-
mulation callege since the active drug was actually formed
during the production process. The drug is an alkylating
agent and the free acid form is hygroscopic, unstable in the
bulk form and degrades rapily in solution. Therefore, the
compound is supplied as the stable ditertiary butyl ester
precursor, which is dissolved in pure formic acid and then
incubated at IOC for 48 h to hydrolyse the ester groups. The
formic acid is then removed by freeze drying to provide the
free acid in the dry state. The freeze-drying cyce required
optimisation to remove residual water [originating from the
formic acid (1-2%)J, which would otherwise induce chemical
instability, and secondary drying at 30C for 20 h was
required. The secondary drying temperature could not be
elevated any further since high temperatres also degraded
the free acid. The lyophiised material was stable for up to 1
year if stored at 4C, but degradation was apparent within 2
weeks at temperatures of20-25C. The prodrug was used for
phase I trials of antibody-directed enzyme prodrug therapy
(ADEPT), but because of the chemical hazard of using for-
mic acid during manufacturing other more stable prodrugs
have been developed.
SRI62-834
SRI 62-834 (Figure 12) is a synthetic phospholipid analogue
with a single long-chain hydrocarbon that is chemically
stable in solution as it lacks a glyceride ester linkage. It is
soluble in aqueous systems at 20C to the extent of 50% (w/
v) and higher concentrations around 75% (w/v) form ckar
viscous gels. The solid material is hygroscopic and equilib-
rates non-stoichiometrically to a gum, requiring hdling in
dry nitrogen and storage at -20C with desication. In
solution it behaves as a surfactant, forming micees, and at
the formulation concentration of 25 mgml-l behaves
osmotically as a compound offive times its molkular weight.
SRI 62-834 has a very high temperature solubility coeffiient,
and test formulations in saline-citrate buffer could be steril-
ised by autoclaving. On storage, however, the drug
precipitates on cooling, and paradoxically is difficult to redis-
solew. Simple aqueous formulations were, however, ruled out
owing to irritation at the site ofinjection, and an alternative
system using Intraipid was developed. This formulation is
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chemically and physically stable for 3 months, but after this
time emulsion breakdown is evident with creaming at 20-C
and coalscence at 50'C. Assay for drug content, however,
reveals that little chemical degradation has taken place even
at the higher temperatures. Because ofthe physical instability
of this agent in solution a useful formulation has yet to be
developed. Although in vitro results have been intresting,
further development is unlkely since only the racemic form is
available.
Trimelawmi
Trimelamol (NSC-283162, Figure 13) is a synthetic analogue
of pentamethylelamine and hexamethylmelamine which
does not require in wivo metabolic activation (Rutty et al.,
1986) and is active against B16 nmlanoma, colon 26, L1210
leukaemia, P388 leukaemia and other tumour models. The
compound is soluble in water (-IOmgmP-'), DMA
(-375mgml-'), propylene glycol (-15mgml-') and 95%
ethanol (-45mgml-'). The stability of trimelamol was
monitored by HPLC at 25C as a function ofpH (pH values
of 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12.5), maximum stability was
at pH 10-11 with a half-life >30 h. Decomposition was
ignificntly faster at lower pH values and at pH 12.5. Dur-
ing decomposition an extremely insoluble dimer is formed
and a precipitate starts to appear a few minutes after the
compound dissolves. Additional stability and mhanistic
studies related to trimelamol decomposition have been pub-
lished recently (Jackson et al., 1991). A lyophilised formula-
tion was developed for clinical trial containing 250mg of
trimelamol and 500mg of mannitol in a 100 ml vial. The
formulation was reconstituted with 5% dextrose in water to a
concentration of 4mgml-' and was used during phase I and
limited phase H trials. As a single administration the max-
imum tolerated dose (MTD) was 2400mgm-2, while on a
thrice-daily schedule it was 1000mgm2 (Judson et al.,
1989). The substantial doses required and the limited
solubility of tlamol necessitated the administration of
large volumes which was further complicated by the rapid
precipitate formation. Because of these dificultis additional
efforts have been directed at improving the trilamol for-
mulation. Gibson et al. (1990) studied the solubility and
stability in numerous vehicles including, DMSO, triacetin,
polyvinylpyrrolidones, HPCD and polyethylene glycols of
various molcular weight ranges. A new freeze-dried formula-
tion was proposed consisting of a 50% aqueous PEG 3400
solution containing 30mgml-' of trimelamol. The freeze-
dried cake reportedly was readily reconstituted with water
and was stable (t/2 = 46.3 h) if not further diluted. However,
the reported phase I dose of 800mgm2 (Judson et al.,
1991) to a 2 m2 patient would require the administration of
more than 25 g ofPEG 3400. Additional toxicological studies
may be required before initiation of clinical trials using this
formulation. Other approaches based on the development of
analogues of trimelamol are also under investigation.
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V489
V489 (NSC-279162, Figure 14) is only very slightly soluble in
water, aqueous co-solvent syss and biocompatible
solvents including DMSO. The compound is highly reactive
and unstable both in solution and in its native liquid state
and thus presented unusual formulation problems. The liquid
degrades rapidly in the prese of smal quantities of
impurities and air, even at temperatures of -20-C. However,
if pure and stored under nitrogen or argon the compound is
stable for prolonged periods even at temperatures of 37C. In
alcoholic solution there is a concentration-dependent reaction
with the alcohol. Low concentrations (0.1%, w/v) react
slowly (10% degradation in 2 months), but higher concentra-
tions (10%, w/v) produce a rapid reaction (70% degadation
after 8 h at 25C) catalysed by an acidic breakdown product
of the low concentration reaction. This produces an unusual
stability profile as the reaction rate increases owing to build-
up ofthe acidic intermediate. Small quantities of water in the
alcohol inhibit the degradation process. Formulation was
achieved by filter steiising the liquid and packing in
ampoules under an inert gas blanket with the final formula-
tion produced just before administration in a two-stage pro-
cess. First the liquid is dissolved in alcohol to provide a
44% (w/v) solution, which is then mixed with Intralipid 20%
using ultrasonication for 4min, to produce a final concentra-
tion of 4% (w/v) V489. The time between the first and
second stages had to be less than 8 mm so that the extent of
degadation was less than 1% at 20C. Tlwhe Intralipid-
solubilised material was chemically stabilsed by the two-
phase system, as the water soluble acid degradation product
partitioned into the aqueous phase while the V489 parti-
tioned into the anhydrous emulsion droplets. The recons-
tituted emulsion was chemically and physically stable for up
to 3 days with less than 5% chemial degradation at room
temperature. Storage greater than 3 days resulted in a rapid
emuion breakdown occurng over periods of a few hours.
Emulsion cracking which was accelrated by high
temperaturs and retarded at low temperatures appeared to
be due to a build-up of chemical breakdown products in the
system. At present, development of this agent is on hold
because of poor results during toxicity testing.
Exdk pol
The development of extraordinary formulation systems,
although providing the drug in a suitable stable form for
adminisLtation, can present further problems. Usually these
are associated with the use of excpients which themselves
have toxicological implications that limit the total quantity of
formulation that can be inistered.
Temozolomide
Temozolomide (Figure 15) is the methyl analoge of
mitozolomide, a chloroethylimidazotetrazinone which has
been evaluated in phase I and phase II clinial trials.
Mitozolomide exhibits some anti-tumour activity in the clinic
but trials were terminated because of unpredictable throm-
bocYtopenia. Temozolomide was known to be less potent
than mitozolomide in murine anti-tumour tests, and was also
less soluble in DMSO. Owing to the limited solubility of
mitozolomide and temozolomide, a product formulated in
DMSO was used in i.v. administration with temozolomide
formulated at a concentration of 30mgm1'I. It was not
0oCCH3
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possible to obtain an i.v. LD1o in the mouse with the DMSO
formulation, however an LD,O estimate was obtained by
intraperitoneal (i.p.) administrtion of a suspension. Since it
was known that temozolomide is ess toxi than mitozolo-
mide and the recommended phase H dose for mitozolomide
was 90-100 mgm 2, it was decided that 50mgm 2 would be
a safe starting dose for the temozolomide phase I trial.
DMSO proved to be an unpopular choice of co-solvent with
the nursing staff as the patients exhaled the metabolite
dimethylsulpide, which had a characteristic unpleasant
odour!! From previous experience, this became a problem
when the total volume min reached 20ml ofDMSO.
It was decided that a maximum 15 ml dose of DMSO would
be administered i.v., limiting temozolomide dose escalation to
200mg m2. At this dose patients were also given an oral
formulation and the measured bioavailability was virtually
100% with a rapid adsorption. Further dose escalations were
conducted with an oral formulation and there was no
evidence of dose dependency in the pharmacokinetics. Fol-
lowing the determination of the MTD the administration
schedule was switched to daily for five consecutive days, and
it was on this schedule that activity aginst gliomas was
evident (Stevens and Newlands, 1993). The results from
phase II trials against glioma and melanoma are currently
under review, and it is hoped to commence further trials with
a view to marketing in the near future.
4-Hydroxyanisole
4-Hydroxyanisole (Figure 16) had previously undergone
phase I clinical trial (Rustin et al., 1992), but it was decided
to attempt to deliver total intravenous doses of up to 35 g.
The drug's solubility in ethanol enabled this to be used as the
vehicle with a final concentration of 600mgml-', which
could be diluted before administration in 0.9% sodium
chloride injection. The restraining factor with this formula-
tion was the absolute volume of ethanol that could be
infused per hour, which was limited by the rate of ethanol
metabolism. If the infusion rate exceeded the metabolic rate
it would result in the patients becoming intoxicated, which
only happened on a few occasions. Hepatotoxicity was
observed during the phase I trial but there was no evidence
that this was ditly related to the formulation's ethanol
content.
The examples above graphically illustrate the many and
varied problems associated with the pharmaceutical develop-
ment of new anti-cancer agents. In the majority of cases it
was possible to develop adequate formulations that permitted
trials to determine the agent's possible clinical utility. How-
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ever, in several cases, despite intense research, development
of a suitable formulation proved impossible and some very
active compounds were excluded from clinical trials. Poor
water solubility and inadequate chemical stability were the
main reasons hindering the design of appropriate formula-
tions. New formulation approaches to solubilise and stabilise
drugs are therefore urgently needed, and this requires in-
creased basic pharmaceutical research and an infusion of new
ideas and approaches. In addition, medicinal chemists must
realise the possible pharmaceutical limitations of putative
agents and attempt to design appropriate in vivo friendly
analogues. Many recent compounds with interesting anti-
tumour activity are also very potent (e.g. bryostatin and
carzelesin), and as such require special consideration. Not
only will suitable formulations need to be developed, but also
much thought and attention must be given to handling pro-
cedures, clean-up procedures and analytical methods. These
must be sufficiently sensitive to monitor effectiveness of
clean-up and also the potential of worker exposure when the
formulation is produced on a large scale. Special techniques
will also be required to minimise loss of these agents by
adsorption during administration.
During the past several years a large number of potential
new compounds have been developed under the auspices of
the JFWP. The JFWP has been the medium for an extensive
exchange of pharmaceutical knowledge between CRC,
EORTC and NCI and has facilitated the resolution of several
formulation problems. It is essential that high quality stan-
dards are maintained and further sharpened with sufficient
data acquired during development to permit acceptance by
the regulatory authorities. Such a move would be another
step in speeding the development process from putative agent
to useful product. Much has been achieved; however much
also remains to be done. Hopefully the JFWP will play an
important role in this effort.
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